Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Apr 06, 2022 10:26am
92 Views
Post# 34580294

RE:Warrants

RE:Warrants
polo22 wrote: Mr Bailey can they extended ...!!!


TXS Policy for Amending Warrant Terms

3. Amending Warrant Terms
 
3.1 General
 
The amendment of Warrant terms may be considered to be the distribution of a new security under Securities Laws and require prospectus and securities registration exemptions.  Issuers should consult legal counsel before applying for an amendment to Warrant terms.  
 
Any amendment of Warrant terms is subject to Exchange acceptance.  An Issuer can apply to the Exchange to amend the terms of a class of Warrants issued pursuant to a Private Placement if it meets the following conditions:
 
a)the Warrants are not listed for trading;
b)    the exercise price of the Warrants is higher than the current Market Price;
c)     no Warrants of the class have been exercised within the last six months;
d)    the Warrants were not issued to an Agent, broker or finder as compensation for services;
e)     at least two weeks remain before the expiry date of the Warrants;
f)      and the Issuer has issued a news release disclosing its intent to amend the Warrants, the particulars of the proposed amendments and the fact that the amendments are subject to Exchange acceptance.

[url=chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.tsx.com%2Fresource%2Fen%2F1055&pdffilename=policy-4.pdf]TSX Private Placement Policy[/url]
<< Previous
Bullboard Posts
Next >>